Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.

Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...

Novartis is making two investments in new radiopharmaceutical manufacturing sites in the US. The Swiss pharmaceutical giant will open a third US radioligand plant in Carlsbad, California, to serve the ...

Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".

Bristol Myers Squibb, AstraZeneca, Eli Lilly and other drug companies have invested some $10 billion on promising cancer ...

Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

Novartis Pharma AG, affiliated to Swiss drug major Novartis AG (NVS), announced Monday updated analysis from the pivotal Phase III ...

Pharmaceutical heavyweights like Bristol Myers Squibb, AstraZeneca, and Eli Lilly are betting big on radiopharmaceuticals, ...

Data science is one of the most current career choices today, especially in a data-driven world. Today, more businesses rely on data for making strategic decisi ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...